File
Authors
Komatsu, Hiroaki Department of Obstetrics and Gynecology, Japanese Red Cross Yamaguchi Hospital
Taniguchi, Fuminori Division of Reproductive-Perinatal Medicine and Gynecologic Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine Researchers DB KAKEN
Harada, Takashi Division of Reproductive-Perinatal Medicine and Gynecologic Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine Researchers DB KAKEN
Nakaso, Takaya Division of Reproductive-Perinatal Medicine and Gynecologic Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine
Nishimura, Noriko Department of Obstetrics and Gynecology, Japanese Red Cross Yamaguchi Hospital
Tsukihara, Satoru Department of Obstetrics and Gynecology, Japanese Red Cross Yamaguchi Hospital KAKEN
Sarugami, Masako Department of Obstetrics and Gynecology, Japanese Red Cross Yamaguchi Hospital
Harada, Tasuku Division of Reproductive-Perinatal Medicine and Gynecologic Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine Researchers DB KAKEN
Kanamori, Yasunobu Department of Obstetrics and Gynecology, Japanese Red Cross Yamaguchi Hospital
Keywords
premature labor
ulinastatin
urinary trypsin inhibitor
Abstract
Background: We evaluated the necessity of urinary trypsin inhibitor for patients with threatened premature labor.
Methods: We enrolled 146 women with singleton pregnancies who were treated for threatened premature labor as inpatients. The uterine cervical length of each patient was ≤ 25 mm at 22–35 weeks of gestation on transvaginal ultrasonography. The patients were divided into two groups: the urinary trypsin inhibitor group (91 patients treated with urinary trypsin inhibitor daily) or non-urinary trypsin inhibitor group (55 patients not treated with urinary trypsin inhibitor). The childbirth outcomes were retrospectively assessed.
Results: The median cervical length measured on the day of admission was almost similar between the urinary trypsin inhibitor and non-urinary trypsin inhibitor groups. Depending on the symptoms of uterine contractions, we determined whether ritodrine hydrochloride and/or magnesium sulfate would be appropriate for treatment. The median gestational week at birth was 38 weeks in the urinary trypsin inhibitor group, and no obvious differences were observed when compared with the non-urinary trypsin inhibitor group. With regard to birth weight, no significant difference was found between the two groups (urinary trypsin inhibitor group, 2776 g; non-urinary trypsin inhibitor group, 2800 g).
Conclusion: Our data showed no significant beneficial effects of urinary trypsin inhibitor in the maternal course and delivery outcomes.
Publisher
Tottori University Medical Press
Content Type
Journal Article
Link
ISSN・ISBN
05135710
NCID
AA00892882
Journal Title
Yonago Acta Medica
Current Journal Title
Yonago Acta Medica
Volume
62
Issue
2
Start Page
204
End Page
210
Published Date
2019-06-20
Publisher-DOI
Text Version
Publisher
Rights
注があるものを除き、この著作物は日本国著作権法により保護されています。 / This work is protected under Japanese Copyright Law unless otherwise noted.
Citation
Hiroaki Komatsu, Fuminori Taniguchi, Takashi Harada, Takaya Nakaso, Noriko Nishimura, Satoru Tsukihara, Masako Sarugami, Tasuku Harada, Yasunobu Kanamori, Re-evaluation of Urinary Trypsin Inhibitor on Pregnancy Course in Patients with Threatened Preterm Delivery: A Single-Center Retrospective Study, Yonago Acta Medica, 2019, Volume 62, Issue 2, Pages 204-210
Department
Faculty of Medicine/Graduate School of Medical Sciences/University Hospital
Language
English